返回 A A A Font Size Receive E-mail Alerts Press Releases

Firehawk® Gains Regulatory Approval in Myanmar

[2018-03-29] 

Naypyidaw, Myanmar - Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") received the regulatory approval from Myanmar authority for its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). It is the first time for MicroPort® products to gain regulatory approval in Myanmar.
 
Firehawk® is the result of eight years of research and development of MicroPort® and it is the world's first and only target-eluting stent ("TES"). It is a new-generation drug-eluting stent of MicroPort® for the treatment of coronary artery stenosis or occlusion after Firebird® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird®") and Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®"). Firehawk® adopts TES Technology platform, and its coating area is only 20% of the stent surface. Firehawk®'s drug is released over 90 days and its polymer is fully absorbed in nine months. Its average metal coverage rate is 14.0-16.1%. Firehawk® is the world's lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy.
 
Previously, Firehawk® gained CE mark, approval from China Food and Drug Administration and regulatory approval in more than 30 countries including India, Thailand, Indonesia, Brazil, Argentina, and Colombia. The approval of Firehawk® in Myanmar represents a milestone in the development of the local market as well as the market expansion of Firehawk®. In the future, MicroPort® will continue to offer more high quality medical device to the Myanmar market to benefit local patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Scientific India Attends Annual Arthroplasty Conference Hyderabad
[Next]:Foxtrot™ NC PTCA Gains Regulatory Approval in Malaysia